Home Cart Sign in  
Chemical Structure| 88426-33-9 Chemical Structure| 88426-33-9

Structure of Buparvaquone
CAS No.: 88426-33-9

Chemical Structure| 88426-33-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Buparvaquone is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone and it is a promising compound for the therapy and prophylaxis of all forms of theileriosis.

Synonyms: BW 720C; Butalex

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Buparvaquone

CAS No. :88426-33-9
Formula : C21H26O3
M.W : 326.43
SMILES Code : O=C1C(CC2CCC(C(C)(C)C)CC2)=C(O)C(C3=C1C=CC=C3)=O
Synonyms :
BW 720C; Butalex
MDL No. :MFCD01712789
InChI Key :NEGDTWQGGLJCTL-UHFFFAOYSA-N
Pubchem ID :71768

Safety of Buparvaquone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
F100TpM cells 4.2 nM 48 h Evaluate the inhibitory effect of Buparvaquone on F100TpM cell proliferation, IC50 of 4.2 nM Int J Parasitol Drugs Drug Resist. 2019 Apr;9:80-86
Echinococcus multilocularis metacestodes 2.87 μM (IC50) 5-12 days To evaluate the in vitro activity of Buparvaquone against E. multilocularis metacestodes, results showed significant damage to the parasites. Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):440-450
Human foreskin fibroblasts (HFF) 0.5 μM, 1 μM 6-9 days To assess the parasiticidal activity of Buparvaquone, results showed it took 9 days at 0.5 μM and 6 days at 1 μM to kill the parasites. Int J Parasitol Drugs Drug Resist. 2015 Feb 13;5(1):16-25
Human foreskin fibroblasts (HFF) 4.9 nM (IC50), 100 nM (IC100) 4 days To evaluate the inhibitory effect of Buparvaquone on N. caninum tachyzoite replication, results showed it effectively inhibited tachyzoite replication. Int J Parasitol Drugs Drug Resist. 2015 Feb 13;5(1):16-25
Theileria annulata-infected cells 50 ng/mL 48 h To evaluate the anti-parasitic activity of BPQ against Theileria annulata-infected cells. Results showed an IC50 value of 50 ng/mL for BPQ. Cell Commun Signal. 2023 Apr 17;21(1):78
T. parva-infected TpMD409 cells 200 ng/ml 72 h To evaluate the antiparasitic activity of Buparvaquone on Theileria-infected cells, results showed that Buparvaquone reduced parasite load and host cell viability. Nature. 2015 Apr 16;520(7547):378-82
T. annulata-infected TBL3 cells 200 ng/ml 72 h To evaluate the antiparasitic activity of Buparvaquone on Theileria-infected cells, results showed that Buparvaquone reduced parasite load and host cell viability. Nature. 2015 Apr 16;520(7547):378-82

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Horses Horses chronically infected with Theileria haneyi Intramuscular 2.5 mg/kg and 6 mg/kg Four times at 4-day intervals To evaluate the efficacy of BPQ in the treatment of T. haneyi in chronically infected horses. Results showed that treatment with 2.5 mg/kg of BPQ led to a rapid abatement of T. haneyi levels, to a level where the parasites were not detectable by nested PCR. Following treatment, the horses remained PCR negative for a minimum of seven weeks until recrudescence occurred. Subsequent re-administration of buparvaquone at an increased dosage of 6 mg/kg upon recrudescence failed to exert a theilericidal effect on T. haneyi. Parasit Vectors. 2024 Aug 12;17(1):337
Balb/c mice Secondary alveolar echinococcosis model Oral 100 mg/kg Three doses per week for four weeks To evaluate the therapeutic efficacy of Buparvaquone in vivo against E. multilocularis infection, results showed the drug failed to significantly reduce parasite burden. Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):440-450
CD1 mice Toxoplasma gondii ME49 oocyst infection model Oral 50 mg/kg Once daily for 5 days To evaluate the therapeutic efficacy of Buparvaquone against congenital toxoplasmosis. Results showed that Buparvaquone treatment significantly increased the survival rate of pups and reduced cerebral infection. J Antimicrob Chemother. 2017 Aug 1;72(8):2334-2341
Dogs Dogs naturally infected with Babesia microti-like piroplasm Intramuscular 5 mg/kg Twice, 48 hours apart To evaluate the efficacy and safety of buparvaquone combined with azithromycin in treating dogs naturally infected with Babesia microti-like piroplasm. Results showed better clinical improvement in the BUP group at 90 and 360 days post-treatment, but PCR still detected infection in some dogs. Parasit Vectors. 2017 Mar 13;10(1):145
Zebrafish Zebrafish xenograft model Not specified 200 ng/ml 72 hours To evaluate the inhibitory effect of Buparvaquone on tumor growth in vivo, results showed that Buparvaquone significantly inhibited tumor growth of infected cells. Nature. 2015 Apr 16;520(7547):378-82

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.06mL

0.61mL

0.31mL

15.32mL

3.06mL

1.53mL

30.63mL

6.13mL

3.06mL

References

 

Historical Records

Categories